|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of SMS1 attenuates AD-like pathology through promoting lysosomal degradation of BACE1.
|
30243987 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
These data suggest that SMS1 is involved in lupus-like autoimmunity via regulating BCR signal transduction and B cell activation.(Word count for the abstract: 230).
|
31262710 |
2019 |
|
Encephalitis, St. Louis
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 knockout lupus-like animal model and SLE patient samples were utilized.
|
31262710 |
2019 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Conclusions</i>: SMS1 and SMS2 showed opposite associations with glioma patient survival, glioma cell growth and response to 2OHOA treatment.
|
30646599 |
2019 |
|
Hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Hepatitis A
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Lupus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 deficiency also displayed lower autoantibody titers and 24 h urine protein excretion in bm12-induced lupus, which were associated with reduced B-cell activation.
|
31262710 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 deficiency also displayed lower autoantibody titers and 24 h urine protein excretion in bm12-induced lupus, which were associated with reduced B-cell activation.
|
31262710 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 knockout lupus-like animal model and SLE patient samples were utilized.
|
31262710 |
2019 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our study indicates that SMS1 downregulation in melanoma enhances GlcCer synthesis, triggering an imbalance in the SM/GlcCer homeostasis, which likely contributes to melanoma progression.
|
31114500 |
2019 |
|
Renal fibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Kindlin-2 levels are negatively correlated with MOB1 and phosphorylated (p) YAP in samples from patients with renal fibrosis.
|
31825843 |
2019 |
|
Lupus Erythematosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 deficiency also displayed lower autoantibody titers and 24 h urine protein excretion in bm12-induced lupus, which were associated with reduced B-cell activation.
|
31262710 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Overall, the present results suggested that SMS1 could inhibit EMT and the migration and invasion of MDA‑MB‑231 cells via TGF‑β/Smad signaling pathway.
|
30535436 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 and SMS2 also had opposing effect on GBM cell survival and 2OHOA's IC<sub>50</sub> correlated with basal SMS1 levels and treatment induced changes in SMS1/SMS2 ratio.
|
30646599 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, the expression of specific enzymes of sphingolipid metabolism, dihydroceramide desaturase 1 and sphingomyelin synthase 1, was increased in the PBMCs of individuals with type 2 diabetes.
|
28988346 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Bcr-Abl (break-point cluster region-abelson), the oncogenic trigger of chronic myelogenous leukemia (CML), has previously been shown to up-regulate the expression and activity of sphingomyelin synthase 1 (SMS1), which contributes to the proliferation of CML cells; however, the mechanism by which this increased expression of SMS1 is mediated remains unknown.
|
29533737 |
2018 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, it remains unclear whether other MST-MOB complexes are also involved in regulating Hippo-YAP signaling and have potential roles in PC.
|
30072378 |
2018 |
|
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, it remains unclear whether other MST-MOB complexes are also involved in regulating Hippo-YAP signaling and have potential roles in PC.
|
30072378 |
2018 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MOB1, a core component of the Hippo signaling pathway, suppresses cell proliferation, and MOB1 liver conditional knockout mice develop intrahepatic cholangiocarcinoma (ICC).
|
28448997 |
2017 |
|
Developmental delay (disorder)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We examined pharyngeal pumping and observed that clozapine-induced inhibition of pharyngeal pumping requires sms-1, a finding that may explain the role of the gene in mediating clozapine-induced developmental delay/lethality.
|
27711049 |
2017 |
|
Global developmental delay
|
0.010 |
Biomarker
|
disease |
BEFREE |
We examined pharyngeal pumping and observed that clozapine-induced inhibition of pharyngeal pumping requires sms-1, a finding that may explain the role of the gene in mediating clozapine-induced developmental delay/lethality.
|
27711049 |
2017 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Human MOB1/glyseraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression was significantly decreased in the tumor of lung cancer tissue (3.347 +/- 4.306) compared with normal lung tissue (4.833 +/- 4.306; P = 0.0437), although 22 of 60 lung cancer tissue samples had > 1 tumor-normal ratio of MOB1/GAPDH mRNA expression.
|
17311693 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Human MOB1 expression in non-small-cell lung cancer.
|
17311693 |
2007 |